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Under certain experimental conditions, neurotrophic factors may reduce epileptogenesis. We have previously
reported that local, intrahippocampal supplementation of fibroblast growth factor-2 (FGF-2) and brain-derived neuro-
trophic factor (BDNF) increases neurogenesis, reduces neuronal loss, and reduces the occurrence of spontaneous
seizures in a model of damage-associated epilepsy. Here, we asked if these possibly anti-epileptogenic effects might
involve anti-inflammatory mechanisms. Thus, we used a Herpes-based vector to supplement FGF-2 and BDNF in rat
hippocampus after pilocarpine-induced status epilepticus that established an epileptogenic lesion. This model causes
intense neuroinflammation, especially in the phase that precedes the occurrence of spontaneous seizures. The sup-
plementation of FGF-2 and BDNF attenuated various parameters of inflammation, including astrocytosis, microcytosis
and IL-1b expression. The effect appeared to be most prominent on IL-1b, whose expression was almost completely
prevented. Further studies will be needed to elucidate the molecular mechanism(s) for these effects, and for that on
IL-1b in particular. Nonetheless, the concept that neurotrophic factors affect neuroinflammation in vivo may be
highly relevant for the understanding of the epileptogenic process.
Findings
Many acquired epilepsies have an identifiable cause,
such as head trauma, an episode of status epilepticus
(SE), stroke, or brain infection [1]. It is thought that
these insults set in motion a cascade of neurobiological
events that, in time, will lead to the occurrence of spon-
taneous seizures and to the diagnosis of epilepsy. This
phenomenon is termed “epileptogenesis”.C o n v e n t i o n a l
“antiepileptic” agents may exert symptomatic effects on
seizures but do not interfere with epileptogenic pro-
cesses [2].
In principle, understanding the molecular mechanisms
underlying the cellular alterations occurring during epi-
leptogenesis (which include cell death, axonal and den-
dritic plasticity, neurogenesis, neuroinflammation and
functional alterations in ion channel and synaptic prop-
erties) should allow development of effective agents. In
this respect, neurotrophic factors (NTFs) appear to be
strong candidates, because an extensive literature
demonstrates their involvement in many of the cellular
alterations associated with epileptogenesis [3]: not only
do their trophic effects suggest involvement in cell
death, neurogenesis and axonal sprouting, but they also
exert functional effects at the synaptic level, with dis-
tinct modulatory actions at excitatory and inhibitory
synapses [4]. In fact, we have recently reported that viral
vector-mediated supplementation of two NTFs, namely
fibroblast growth factor-2 (FGF-2) and brain-derived
neurotrophic factor (BDNF), in a lesioned hippocampus
favors “good” neurogenesis, repairs neuronal damage
and may prevent epileptogenesis [5].
Recently, central nervous system (CNS) inflammation
associated with blood-brain barrier (BBB) leakage has
been implicated in the progression to epilepsy [6-9], and
* Correspondence: michele.simonato@unife.it
† Contributed equally
1Section of Pharmacology, Department of Clinical and Experimental
Medicine, and Neuroscience Center, University of Ferrara, Italy
Full list of author information is available at the end of the article




© 2010 Bovolenta et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.the pro-epileptogenic role of neuroinflammation has
received great attention [10-13]. However, it is still
unknown if NTFs may modulate these phenomena.
The aim of this study was to analyze if NTFs-induced
anti-epileptogenic effects may involve anti-inflammatory
mechanisms. We used a previously generated viral vec-
tor [5] to supplement FGF-2 and BDNF in the hippo-
campus after pilocarpine-induced SE that established an
epileptogenic lesion. We decided to start investigating
IL-1b expression and glial activation in controls and
inoculated animals. An increase in inflammatory cyto-
kines, IL-1b in particular, has been reported in the CNS
and plasma in experimental models of seizures and in
clinical cases of epilepsy [14]. Astrocytic and microglial
activation elicited by pilocarpine-induced SE could
underlie epileptogenic mechanisms [15,16] and BBB
alterations [17]. A detailed description of the methods
employed in this study is provided as Additional file 1.
In the pilocarpine model, an episode of SE produces,
after a latent period of a few days, spontaneous recur-
rent seizures (SRSs), i.e. epilepsy. Pilocarpine (300 mg/
kg i.p.) rapidly induced a robust convulsive SE (latency:
18 ± 2 min), which was interrupted after 2 h by admin-
istering the anticonvulsant diazepam (10 mg/kg i.p.).
Based on behavioral observation and EEG recordings,
the severity of SE in different animals was indistinguish-
able. This procedure caused damage in limbic and
extra-limbic brain areas: in particular, hippocampal
damage and was invariably remarkable [5]. SRSs began
to occur 11 ± 1 days after SE.
Three days after SE, i.e. during latency, these lesioned
animals were randomly assigned to 3 groups: one group
was injected in one hippocampus with the vector
expressing FGF-2 and BDNF (TH-FGF2/0-BDNF),
another was injected with a control vector and the third
was not treated at all (no difference was observed
between these latter 2 groups in the parameters exam-
ined in this and in previous [5] studies and, therefore,
they have been pooled together for statistical analysis).
TH-FGF2/0-BDNF provides a short-term (about a week)
increase in FGF-2 expression accompanied and followed
by a slightly longer-lasting (at least 11 days) increase in
BDNF expression, in the absence of significant toxicity
[5]. As expected on the basis of the ability of HSV to
enter nerve terminals and to be retrogradelly trans-
ported, reaching connected areas, transgene expression
was bilateral, even if more robust at the site of injection
for the first few days [5].
Animals were killed 7, 14 or 28 days after SE (i.e. 4, 11
or 25 days after vector inoculation) to examine possible
effects on neuroinflammation. Continuous video-EEG
monitoring for the occurrence, severity and duration of
seizures was performed starting 7 days after SE. As pre-
viously reported [5], vector-injected rats exhibited
significantly less spontaneous seizures/day compared to
untreated or control vector-injected animals (Table 1).
These seizures were also significantly less severe in vec-
tor-treated rats although, on average, they had the same
duration in both groups (Table 1).
The density of GFAP-positive cells in the hippocam-
pus was significantly increased in pilocarpine-treated
animals compared with naïve controls, an indication of
reactive astrocytosis. In agreement with previous studies
[18], this phenomenon was maximal during latency
(7 days after SE) and then gradually decreased with time
(Figure 1). In pilocarpine animals treated with TH-
FGF2/0-BDNF, the density of GFAP-positive cells initi-
ally increased to about the same level as in those treated
with the control vector (Figure 1A), but then decreased
more rapidly, becoming significantly lower 14 days after
SE (i.e. 11 days after vector inoculation; Figure 1B and
1E-F). However, this did not lead to a complete normal-
ization of astrocytosis, but only to an acceleration of the
process: 28 days after SE (25 days after vector inocula-
tion) the expression of GFAP was identical in the two
groups (Figure 1C).
We then measured the density of microglial cells
using Ox42 immunohistochemistry. Similar to GFAP-
positive cells, the density of Ox42-positive cells in the
hippocampus was significantly increased in pilocarpine-
treated animals compared with naïve controls, an indica-
tion of reactive microgliosis, and this phenomenon was
maximal during latency (7 days after SE), then gradually
decreased in time (Figure 2). In pilocarpine animals
treated with TH-FGF2/0-BDNF, the density of Ox42-
positive cells was initially reduced only in the injected
hippocampus (Figure 2A), then bilaterally (Figure 2B
and 2E-F), paralleling high level transgene expression
[5]. Twenty-eight days after SE it was at baseline levels
(Figure 2C).
In agreement with previous reports [19], IL-1b expres-
sion dramatically increased in pilocarpine-treated ani-
mals compared with naïve controls, in a long-lasting
manner (Figure 3). In pilocarpine animals treated with
the vector expressing FGF-2 and BDNF, this increase in
IL-1b expression was prevented (Figure 3). The observa-
tion of a bilateral effect even at the earliest time-point,




pilo - control vector 3.9 ± 0.6 2.4 ± 0.2 55 ± 15
pilo - FGF2-BDNF 1.2 ± 0.3** 1.5 ± 0.3* 63 ± 16
Average frequency, severity and duration of spontaneous seizures in the
chronic period (14 -28 days after pilocarpine- induced SE, vectors injected 4
days after SE). Data are the means ± s.e.m. for 6 animals per group. **P < 0.01
vs. pilo-control vector; Student’s t test for unpaired data. *P < 0.05 vs. pilo-
control vector; Mann-Whitney U test.
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Page 2 of 6Figure 1 Effects of FGF-2 and BDNF on hippocampal GFAP-positive cells (putative astrocytes). (A-C) Time course of alterations in GFAP
expression, expressed as percent of GFAP-positive pixels in naïve rats (open bars), pilocarpine rats inoculated with the control vector (pilo -
control vector, gray bars) or with the vector expressing FGF-2 and BDNF (pilo - FGF2-BDNF, solid bars) in the right, ipsilateral to inoculation
(I) and in the left, contralateral (C) hippocampus. Analysis has been performed 4 (A), 11 (B) and 25 days (C) after inoculation (DAI), i.e. 7, 14 and
28 days after pilocarpine SE. Data are presented as mean ± s.e.m. for 6 animals per group. *P < 0.05, **P < 0.01 versus naïve;
●P < 0.05,
●●P < 0.01 versus pilo-control vector. One-way ANOVA and post-hoc Newman-Keuls test. (D-F) Representative sections showing GFAP
immunohistochemistry in the CA1 region of naïve rats (D), of pilocarpine rats killed 11 days after control vector injection (E) and of pilocarpine
rats 11 days after FGF2-BDNF vector injection (F). The pattern of changes observed in CA1 was identical for the entire hippocampus. Horizontal
bar = 50 μm.
Figure 2 Effects of FGF-2 and BDNF on hippocampal Ox42-positive cells (putative microglia). (A-C) Time course of the alterations in Ox42
expression, expressed as percent of Ox42-positive pixels. See Figure 1 for details. Data are presented as mean ± s.e.m. for 6 animals per group.
*P < 0.05, **P > 0.01 versus naïve;
●P < 0.05,
●●P < 0.01 versus pilo-control vector. One-way ANOVA and post-hoc Newman-Keuls test. (D-F)
Representative sections showing Ox42 immunohistochemistry in the CA1 region of naïve rats (D), of pilocarpine rats killed 11 days after control
vector injection (E) and of pilocarpine rats 11 days after FGF2-BDNF vector injection (F). The pattern of changes observed in CA1 was identical
for the entire hippocampus. Horizontal bar = 50 μm.
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low [5], indicates that low-level FGF-2 and BDNF sup-
plementation may be sufficient to prevent IL-1b expres-
sion. Compared with pilocarpine animals, no change in
any of the investigated parameters was observed in TH-
FGF2/0-BDNF-treated animals in areas where transgene
expression did not occur, such as neocortex (data not
shown).
This study suggests that NTFs may affect neuroin-
flammation in vivo: the local, viral vector-mediated, sup-
plementation of FGF-2 and BDNF in a lesioned,
epileptogenic hippocampus attenuates various para-
meters of inflammation, including astrocytosis, microcy-
tosis and IL-1b expression. The effect appears to be
most prominent on IL-1b, whose expression is almost
completely prevented, even at earliest time-point and for
relatively low-level transgene expression.
Neuroinflammation appears to be highly implicated in
epileptogenesis. Leukocyte-endothelium interaction may
result in leukocyte extravasation and BBB permeabiliza-
tion, favoring the induction of spontaneous seizures
[10,13,20,21]. Integrin activation and BBB leakage are
t h o u g h tt oe x e r tap r o e p i l e p t i cr o l eb ym o d u l a t i n gt h e
release of cytokines and chemokines, which are known
to modulate intercellular signaling within the CNS
[22-25]. Very little is known regarding the possible mod-
ulation of these phenomena by NTFs. However, BDNF
is upregulated in rodents after inflammatory challenges
[26]. Also, BDNF and its receptor trkB are expressed in
macrophages [27] and play autocrine and paracrine
roles in the modulation of regeneration and angiogen-
esis following nerve injury [28]. Moreover, recent data
suggest that pro-BDNF (the BDNF precursor) is a sup-
pressing factor for macrophage migration and infiltra-
tion and may play a detrimental role after spinal cord
injury [29].
CNS inflammation is associated with BBB breakdown,
and BBB leakage has been implicated both in the induc-
tion of seizures and in the progression to epilepsy [6-9].
In addition, BBB opening leads by itself to epileptiform
activity, mediated by exposure of astrocytes and neuro-
nal cells to blood albumin and potassium ions, respec-
tively [6,7]. In support of the results obtained from
animal models, it has been shown that BBB disruption
by intra-arterial injection of mannitol in human patients
suffering from cerebral lymphoma induces focal motor
seizures [9]. NTFs may be involved in preserving BBB
integrity: intracerebroventricular administration of
BDNF has been reported to significantly reduce BBB
breakdown, brain edema formation, and cell/tissue
injury [30]; moreover, FGF-2 also plays an important
role in the regulation of BBB permeability in vivo [31].
BBB leakage, however, peaks about 4 days after pilo-
carpine-induced SE [32], while significant FGF-2 and
BDNF overexpression is achieved only a few days after
vector injection, i.e. about a week after SE [5,33]. Thus,
Figure 3 Effects of FGF-2 and BDNF on hippocampal IL1b-positive cells. (A-C) Time course of the alterations in IL1b expression, expressed
as percent of IL1b-positive pixels. See Figure 1 for details. Data are presented as mean ± s.e.m. for 6 animals per group. *P < 0.05, **P < 0.01
versus naïve;
●P < 0.05,
●●P > 0.01 versus pilo-control vector. One-way ANOVA and post-hoc Newman-Keuls test. (D-F) Representative sections
showing IL1b immunohistochemistry in the CA1 region of naïve rats (D), of pilocarpine rats killed 11 days after control vector injection (E) and of
pilocarpine rats 11 days after FGF2-BDNF vector injection (F). The pattern of changes observed in CA1 was identical for the entire hippocampus.
Horizontal bar = 50 μm.
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reduction in neuroinflammmatory signs. One alternative
hypothesis is that FGF-2 and BDNF primarily reduce
IL-1b expression, thereby attenuating astrocytosis and
microgliosis [34,35]. This hypothesis is in line with the
temporal sequence of the effects, wherein IL-1b effects
appear earlier than those of GFAP and Ox42. Remark-
ably, the effect on IL-1b is observed before the occur-
rence of SRSs and, thus, cannot be secondary to their
reduction.
In conclusion, the present study provides first evi-
dence that NTF overexpression might modulate the
brain inflammatory response that follows pilocarpine-
induced SE. This effect may underlie the observed
reduction in SRS frequency and, therefore, may repre-
sent an interesting therapeutic approach. Its molecular
mechanism(s) will be explored in the future. Nonethe-
less, the concept that NTFs affect neuroinflammation in
vivo may be highly relevant for the understanding of the
epileptogenic process.
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